Oppenheimer analyst Leland Gershell raised the firm’s price target on Argenx (ARGX) to $704 from $675 and keeps an Outperform rating on the shares. The firm notes Q4 sales of $737M came in as pre-announced, and Vyvgart’s utilization continues to grow through prescriber breadth and depth. Oppenheimer says it lacks clarity on CIDP revenue contribution, but believes this primarily drove the beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $701 from $696 at Citizens JMP
- Argenx price target raised to $741 from $723 at Wells Fargo
- Argenx price target raised to $720 from $717 at H.C. Wainwright
- Argenx Se: Promising Outlook with Vyvgart Momentum and Pipeline Expansion Justifies Buy Rating
- Argenx Reports Strong 2024 Financial Results and Strategic Growth